Dr Yves Fradet graduated from Laval University (Quebec, Canada) in 1981 and completed an oncology fellowship at the Memorial Sloan-Kettering Cancer Center, with Drs Willet Whitmore and Lloyd Old. In 1983 he founded, at the Laval University Cancer Research Center, a translational and clinical research laboratory  in urological cancers whose work are supported continuously for more than 30 years.

Dr Fradet still has a very active practice in uro-Oncology within the Urologic Oncology Section and the Urology Service at the CHU de Québec- Hôtel-Dieu de Québec where he has grouped a team of specialists among the most important in Canada including seven uro-oncologists, three of which are also holders of PhD.

He is a member of many national and international societies, including since 2001, the American Association of Genitourinary Surgeons in which he was invited to be part of the 75 members in America. More recently, he was appointed international honorary member of the Association of Academic European Urology, membership awarded to those who have had important influence on urology. Dr Fradet is often invited as a guest speaker at national and international meetings, as a visiting professor, and as a consultant to many organizations. He was the founding chairman of the Canadian Urologic Oncology Group from 1988 to 1995 and chairman of the Department of Surgery at Laval University from 2000 to 2008. He has authored over 330 publications and book chapters and more than 600 abstracts.

L'Hôtel-Dieu de Québec
10, rue McMahon
1853-1
Québec, Québec
Canada G1R 2J6
319 entries « 1 of 32 »

Gevariya N, Lachance G, Robitaille K, Joly Beauparlant C, Beaudoin L, Fournier E, Fradet Y, Droit A, Julien P, Marette A, Bergeron A, Fradet V

Omega-3 Eicosapentaenoic Acid Reduces Prostate Tumor Vascularity.

Journal Article

Mol Cancer Res, 2020, ISSN: 1541-7786.

Abstract | Links:

Vittrant B, Bergeron A, Molina OE, Leclercq M, Legare XP, Hovington H, Picard V, Martin-Magniette ML, Livingstone J, Boutros PC, Collins C, Fradet Y, Droit A

Immune-focused multi-omics analysis of prostate cancer: leukocyte Ig-Like receptors are associated with disease progression.

Journal Article

Oncoimmunology, 9 (1), pp. 1851950, 2020, ISSN: 2162-4011.

Abstract | Links:

Bilodeau JF, Gevariya N, Larose J, Robitaille K, Roy J, Oger C, Galano JM, Bergeron A, Durand T, Fradet Y, Julien P, Fradet V

Long chain omega-3 fatty acids and their oxidized metabolites are associated with reduced prostate tumor growth.

Journal Article

Prostaglandins Leukot Essent Fatty Acids, 164 , pp. 102215, 2020, ISSN: 0952-3278.

Abstract | Links:

Koti M, Berman DM, Siemens DR, Lange D, Wang E, Toren P, Eigl BJ, Hardy C, Purves R, Fradet V, Fradet Y, Mansure J, Kassouf W, Black PC, Canadian Bladder Cancer Research Network

Building a Canadian Translational Bladder Cancer Research Network.

Journal Article

Can Urol Assoc J, 14 (10), pp. E475-E481, 2020, ISSN: 1911-6470.

| Links:

Turcotte B, Paquet S, Blais AS, Blouin AC, Bolduc S, Bureau M, Caumartin Y, Cloutier J, Deschenes-Rompre MP, Dujardin T, Fradet Y, Lacombe L, Moore K, Morin F, Nadeau G, Simonyan D, Soucy F, Tiguert R, Toren P, Lodde M, Pouliot F

A prospective, multisite study analyzing the percentage of urological cases that can be completely managed by telemedicine.

Journal Article

Can Urol Assoc J, 14 (10), pp. 319-321, 2020, ISSN: 1911-6470.

Abstract | Links:

Toren P, Brisson H, Simonyan D, Hovington H, Lacombe L, Bergeron A, Fradet Y

Androgen receptor and immune cell PD-L1 expression in bladder tumors predicts disease recurrence and survival.

Journal Article

World J Urol, 2020, ISSN: 0724-4983.

Abstract | Links:

Leong DP, Fradet V, Shayegan B, Duceppe E, Siemens R, Niazi T, Klotz L, Brown I, Chin J, Lavallee L, Mousavi N, Luke P, Lukka H, Gopaul D, Violette P, Hamilton RJ, Davis MK, Karampatos S, Mian R, Delouya G, Fradet Y, Mukherjee S, Conen D, Chen-Tournoux A, Johnson C, Bessissow A, Dresser G, Hameed AK, Abdel-Qadir H, Sener A, Pal R, Devereaux PJ, Pinthus J, RADICAL PC Investigators

Cardiovascular Risk in Men with Prostate Cancer: Insights from the RADICAL PC Study.

Journal Article

J Urol, 203 (6), pp. 1109-1116, 2020, ISSN: 0022-5347.

Abstract | Links:

Levesque E, Labriet A, Hovington H, Allain EP, Melo-Garcia L, Rouleau M, Brisson H, Turcotte V, Caron P, Villeneuve L, Leclercq M, Droit A, Audet-Walsh E, Simonyan D, Fradet Y, Lacombe L, Guillemette C

Alternative promoters control UGT2B17-dependent androgen catabolism in prostate cancer and its influence on progression.

Journal Article

Br J Cancer, 122 (7), pp. 1068-1076, 2020, ISSN: 0007-0920.

Abstract | Links:

Grosset AA, Dallaire F, Nguyen T, Birlea M, Wong J, Daoust F, Roy N, Kougioumoutzakis A, Azzi F, Aubertin K, Kadoury S, Latour M, Albadine R, Prendeville S, Boutros P, Fraser M, Bristow RG, van der Kwast T, Orain M, Brisson H, Benzerdjeb N, Hovington H, Bergeron A, Fradet Y, Tetu B, Saad F, Leblond F, Trudel D

Identification of intraductal carcinoma of the prostate on tissue specimens using Raman micro-spectroscopy: A diagnostic accuracy case-control study with multicohort validation.

Journal Article

PLoS Med, 17 (8), pp. e1003281, 2020, ISSN: 1549-1277.

Abstract | Links:

Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, Ogawa O, Park SH, Lee JL, De Giorgi U, Bogemann M, Bamias A, Eigl BJ, Gurney H, Mukherjee SD, Fradet Y, Skoneczna I, Tsiatas M, Novikov A, Suarez C, Fay AP, Duran I, Necchi A, Wildsmith S, He P, Angra N, Gupta AK, Levin W, Bellmunt J, DANUBE study investigators

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.

Journal Article

Lancet Oncol, 21 (12), pp. 1574-1588, 2020, ISSN: 1470-2045.

Abstract | Links:

319 entries « 1 of 32 »
Signaler des ajouts ou des modifications

Active projects

  • Bourse de doctorat pour le projet de recherche de madame Fahimed Aeineh Negin , Subvention, Fondation du CHU de Québec, from 2020-05-08 to 2021-05-07
  • Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
  • Centre de recherche sur le cancer, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1996-05-01 to 2022-06-13
  • CQDM_Projet de recherche PICT-01 sur le cancer de la prostate , Subvention, Consortium québécois sur la découverte du médicament, Programme conjoint CQDM/Alsace BioValley, from 2019-12-01 to 2022-11-30
  • En route towards prebiotic clinical trials for enhancement of immunotherapies in bladder and prostate cancers, Subvention, The W. Garfield Weston Foundation, Transformational Research, from 2020-06-01 to 2023-05-31
  • Interaction between environment, diet, physical activities, and sexual habits, in the risk of prostate cancer. Validation of biomarkers to personnalize preventive interventions., Subvention, Société de recherche sur le cancer, Compétition GRePEC (SRC/FRSQ/MDEIE), from 2012-10-01 to 2021-12-31
  • projet de recherche en urologie (don dédié de la compagnie Tersera) , Subvention, Fondation du CHU de Québec, from 2020-03-16 to 2021-03-15
  • Stromal Gene Expression Predicts And May Drive Metastasis in Prostate Cancer, Subvention, Instituts de recherche en santé du Canada, Subvention Projet, from 2017-04-01 to 2022-03-31

Recently finished projects

  • Effects of the Leucocytic Infiltration of Intraductal Carcinoma of the Prostate, Partenariat, Société de recherche sur le cancer, Subvention de fonctionnement, from 2017-09-01 to 2019-08-31
  • Effet de la thérapie combinant un anti-PD-1 et le tasquinimod pour le traitement du cancer de la prostate, Subvention, Université Laval - Soutien à la recherche, from 2018-05-01 to 2019-04-30
  • Enhancing bladder cancer immunotherapy efficacy in men using bicalutamide, Subvention, Société de recherche sur le cancer, from 2018-12-01 to 2019-11-30
  • Financement de la phase 1-2-3 du projet de recherche DPX-SurMAGE, Subvention, Fondation du CHU de Québec, from 2019-03-25 to 2020-03-24
  • Inducing prostate tumor eosinophilia to favor prostate cancer immunotherapy , Subvention, Canadian Urological Association Scholarship Foundation, CUA Astellas Research Grant Program 2017, from 2018-06-19 to 2019-06-18
  • lnducing tumor eosinophilia to favor prostate cancer immunotherapy , Subvention, Association canadienne d'urologie, from 2018-11-12 to 2020-03-31
  • Prebiotics to enhance immunotherapy response in bladder cancer, Subvention, The W. Garfield Weston Foundation, 2018 Proof-of-Principle Grant Call, from 2019-01-01 to 2020-12-31
  • Targeting PD-1 and TIGIT pathways for the immunotherapy of bladder cancer, Subvention, Association canadienne d'urologie, from 2018-11-23 to 2019-11-22
  • Toward nutritional and epigenomic interventions in prostate cancer prevention and management, Subvention, Instituts de recherche en santé du Canada, Fonctionnement: Subvention de promotion de l’impact - CCREES, from 2017-10-01 to 2020-09-30
Data provided by the Université Laval research projects registery